Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 37Advanced Breast Cancer 5Neoplasm Metastasis 4Neoplasms 2The Neoadjuvant Therapy 1Solid Tumor, Adult 1Recurrent Uterine Corpus Carcinoma 1Hormone Receptor-positive Advanced Breast Cancer 1Hormone Receptor Positive Advanced Breast Cancer 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1HR Positive/HER-2 Negative Breast Cancer 1Estrogen Receptor-positive Breast Cancer 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasm Female 1Breast Diseases 1Breast Carcinoma In Situ 1Breast Cancer Organoids 1Brain Neoplasms 1

Interventions

Tamoxifen 3Neoadjuvant Therapy 2Amplified Fragment Length Polymorphism Analysis 2Ultrasonography 1Saline Solution 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Mammography 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Immunoenzyme Techniques 1Fulvestrant 1DNA Methylation 1Chemotherapy, Adjuvant 1Carboplatin 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Intraductal, Noninfiltrating × Fulvestrant × Clear all
NCT00126464 2013-11-06

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

National Cancer Institute (NCI)

Phase NA Unknown
100 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡